All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

How I sequence treatment for R/R B-ALL

Jul 28, 2022
Learning objective: After reading this article, learners will be able to cite a new clinical development in ALL

During the last steering committee meeting (SC), held on May 19, 2022, the SC members discussed sequencing treatment in R/R B-ALL. The session was chaired by Hervé Dombret and included Wendy Stock, André Baruchel, Elias Jabbour, Oliver Ottmann, and Mark Litzow.

Key topics of discussion included: “When do you select inotuzumab, blinatumomab, or CAR T-cell therapy” and “Can CAR T-cell therapy replace allo-HSCT.”

How I sequence treatment for R/R B-ALL